A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care

NCT07712484 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Coccidioidomycosis
Disseminated Fungal Infection
Coccidioides Infection
Coccidioides Immitis Infection
Coccidioides Posadasii Infection
Coccidioidomycosis Infection
San Joaquin Valley Fever
Valley Fever

Interventions

DRUG: Olorofim
DRUG: Placebo

Sponsor

F2G Ltd

Collaborators

[object Object]